quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:01:12·32d
SECFiling
Avalo Therapeutics Inc. logo

Avalo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

AVTX· Avalo Therapeutics Inc.
Health Care
Original source

Companies

  • AVTX
    Avalo Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 9UpdateWolfe Research$48.00
  • Apr 6UpdateCitizens$52.00
  • Feb 2UpdateGuggenheim$50.00
  • Dec 18UpdateMizuho$39.00
  • Sep 17UpdateH.C. Wainwright$25.00
  • Sep 5UpdateTD Cowen-

Related

  • SEC13d
    SEC Form DEFA14A filed by Avalo Therapeutics Inc.
  • SEC13d
    SEC Form DEF 14A filed by Avalo Therapeutics Inc.
  • ANALYST15d
    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target
  • INSIDER15d
    SEC Form 4 filed by Doyle Mittie
  • ANALYST18d
    Citizens initiated coverage on Avalo Therapeutics with a new price target
  • INSIDER20d
    SEC Form 4 filed by Sullivan Christopher Ryan
  • INSIDER20d
    SEC Form 4 filed by Doyle Mittie
  • SEC22d
    SEC Form 144 filed by Avalo Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022